Low-dose melittin is safe for intravitreal administration and ameliorates inflammation in an experimental model of uveitis

Castro, Brenda Fernanda Moreira; Silva, Carolina Nunes da; Cordeiro, Lídia Pereira Barbosa; Cenachi, Sarah Pereira de Freitas; Vasconcelos-Santos, Daniel Vítor; Machado, Renes R.; Heneine, Luíz Guilherme Dias; Silva, Luciana Maria; Silva-Cunha, Armando

doi:10.1016/j.crphar.2022.100107

Cited by 4 publications

(2 citation statements)

References 87 publications

(115 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The intraocular anti-inflammatory effect of IVT MF was evaluated in an experimental model of BCG-induced uveitis in rats. The clinical signs of uveitis observed in this work are consistent with those obtained in previous studies using the same experimental model [ 10 , 12 , 18 ]. Compared to vehicle-treated eyes, MF reduced the clinical signs of inflammation on the 3rd day after uveitis induction, similar to DX-treated eyes.…”

Section: Discussionsupporting

confidence: 92%

Efficacy and Safety Evaluation of Mometasone Furoate in Treating Ocular Inflammation

et al. 2023

Self Cite

View full text Add to dashboard Cite

Mometasone furoate (MF) is a medium-potency synthetic glucocorticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. However, its role in the treatment of ocular inflammation has not yet been explored. This work investigated the anti-inflammatory activity of MF in ocular tissues. First, the in vivo safety of the intravitreal (IVT) injection of MF (80, 160, and 240 µg) was evaluated via clinical examination (including the assessment of intraocular pressure), electroretinography (ERG), and histopathology. Second, MF was tested in an experimental model of bacillus Calmette–Guérin (BCG)-induced uveitis in Wistar rats. Intraocular inflammation was then evaluated via a slit-lamp and fundus examination, ERG, histopathology, and the quantification of pro-inflammatory markers. Intravitreal MF showed no toxicity in all the investigated doses, with 160 µg leading to attenuated disease progression and improvement in clinical, morphological, and functional parameters. There was a significant reduction in the levels of inflammatory markers (myeloperoxidase, interleukins 6 and 1β, CXCL-1, and tumor necrosis factor-alpha) when compared to the levels in untreated animals. Therefore, MF should be further investigated as a promising drug for the treatment of ocular inflammation.

show abstract

Section: Discussionsupporting

confidence: 92%

Efficacy and Safety Evaluation of Mometasone Furoate in Treating Ocular Inflammation

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…[27] But investigating the effect of MLT on uveitis (ocular inflammation) demonstrated that intraocular administration of low-dose MLT presents antiinflammatory and antiangiogenic effects, thus rendering MLT a potential candidate for treatment of ocular diseases. [28] In recent years, inhibition of ovarian, breast, liver, and lung cancer cells by bee venom and MLT has been reported. [29][30][31][32] On top of that, various types of evidence studies have confirmed anti-inflammatory, [20] antidiabetic, [33] antiarthritis, [34] antimicrobial, [35] and adjuvant [36] properties of MLT.…”

Section: Introductionmentioning

confidence: 99%

Immunomodulatory activities and biomedical applications of melittin and its recent advances

Jafari,

Sadeghi,

Dehaghi

et al. 2024

Archiv der Pharmazie

View full text Add to dashboard Cite

Melittin (MLT), a peptide containing 26 amino acids, is a key constituent of bee venom. It comprises ∼40%–60% of the venom's dry weight and is the main pricing index for bee venom, being the causative factor of pain. The unique properties of MLT extracted from bee venom have made it a very valuable active ingredient in the pharmaceutical industry as this cationic and amphipathic peptide has propitious effects on human health in diverse biological processes. It has the ability to strongly impact the membranes of cells and display hemolytic activity with anticancer characteristics. However, the clinical application of MLT has been limited by its severe hemolytic activity, which poses a challenge for therapeutic use. By employing more efficient mechanisms, such as modifying the MLT sequence, genetic engineering, and nano‐delivery systems, it is anticipated that the limitations posed by MLT can be overcome, thereby enabling its wider application in therapeutic contexts. This review has outlined recent advancements in MLT's nano‐delivery systems and genetically engineered cells expressing MLT and provided an overview of where the MLTMLT's platforms are and where they will go in the future with the challenges ahead. The focus is on exploring how these approaches can overcome the limitations associated with MLT's hemolytic activity and improve its selectivity and efficacy in targeting cancer cells. These advancements hold promise for the creation of innovative and enhanced therapeutic approaches based on MLT for the treatment of cancer.

show abstract

Melittin enhanced intracellular trehalose with synergistic membrane stabilization of macromolecular protectants for cell cryopreservation

Niu,

Gao,

Zhu

et al. 2024

Sci. China Technol. Sci.

View full text Add to dashboard Cite

Low-dose melittin is safe for intravitreal administration and ameliorates inflammation in an experimental model of uveitis

Cited by 4 publications

References 87 publications

Efficacy and Safety Evaluation of Mometasone Furoate in Treating Ocular Inflammation

Efficacy and Safety Evaluation of Mometasone Furoate in Treating Ocular Inflammation

Immunomodulatory activities and biomedical applications of melittin and its recent advances

Melittin enhanced intracellular trehalose with synergistic membrane stabilization of macromolecular protectants for cell cryopreservation

Contact Info

Product

Resources

About